Hello guys, Welcome to Africa's Largest Video Search Engine, and you are watching Results of RELEVANCE: frontline rituximab-lenalidomide for follicular lymphoma. and this video is uploaded by VJHemOnc – Video Journal of Hematology & HemOnc at 2018-07-30T07:00:53-07:00. We are just promoting this video only for entertainment and educational purpose only. I hop you like our Video Search Engine. [9hwt4oI0OLw]
| Name | Results of RELEVANCE: frontline rituximab-lenalidomide for follicular lymphoma |
| Video Uploader | Video From VJHemOnc – Video Journal of Hematology & HemOnc |
| Upload Date | This Video Uploaded At 30-07-2018 14:00:53 |
| Video Discription | Results of the Phase III RELEVANCE trial (NCT01476787) of rituximab-lenalidomide for untreated follicular lymphoma were presented at the American Society of Oncology (ASCO) 2018 Annual Meeting in Chicago, IL. Nathan Fowler, MD, of the MD Anderson Cancer Center, Houston, TX, discusses these results and their importance here. [9hwt4oI0OLw] |
| Category | Education |
| Tags | Speaker: Nathan Fowler | Event: ASCO 2018 | Format: Interview | Subject: Lymphoma | Subject: Non-Hodgkin Lymphoma | Subject: B-Cell Lymphoma | Subject: Follicular Lymphoma | Field: Treatment | Medicines: Rituximab | Medicines: Lenalidomide | Trial: RELEVANCE | NCT01476787 | clinical trials | Phase III | first-line | frontline | antibodies | CD20 | chemoimmunotherapy | immunomodulatory agents | chemotherapy | remission | response rate | PFS | trial updates | Field: Immuno-Oncology | Medicines: Antibodies |
